Evopoint Biosciences (SHA:688837) has lodged its prospectus for an initial public offering on the Shanghai Stock Exchange's STAR Market board.
The biopharmaceutical company plans to issue up to 65.3 million shares, representing at least 15% of its enlarged share capital post-IPO, according to its prospectus filed Wednesday.
Proceeds will fund research and development and working capital.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.